Immunosuppressive treatment for aplastic anemia: Are we hitting the celling?

Haematologica

Volumn 94, Issue 3, 2009, Pages 310-312

  Passweg, Jakob R ^a,b,c   Tichelli, Andre ^b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; RAPAMYCIN; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; DISEASE SEVERITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; SIROLIMUS; TREATMENT OUTCOME;

EID: 62949229281     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.002329     Document Type: Review

References (23)

1. Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood 1975;45:355-63.
2. Du X-Y, Pumbo E, Ivanovich J, An P, Maziarz RT, Reiss UM, et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 2009;113:309-16.
3. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy - the European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000;37:69-80.
4. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol 2000;37:91-101.
5. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Oki-moto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002;100:786-90.
6. Socie G, Mary JY, Schrezenmeier PL Marsh J, Bacigalupo A, Locasciulli A, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109:2794-96.
7. Speck B, Gluckman E, Haak HL van Rood JJ. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet 1977;2:1145-8.
8. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. The German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11- year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-42.
9. Fuhrer M, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, Friedrich W, et al. Immunosuppressive therapy for aplastic anaemia in children: a more severe disease predicts better survival. Blood 2005;106:2102-4.
10. Marsh J, Schrezenmeier H, Marin P Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anaemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999;93:2191-5.
11. Rosenfeld S, Follman D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia. Association between hematologic response and long-term outcome. JAMA 2003;289:1130-5.
12. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globuilin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midollo Osseo (GITMO). Blood 2000;95:1931-4.
13. Saracco P, Quarello P, Iori AP, Zecca M, Longoni D, Svahn J, et al. on bahalf of the Bone Marrow Failure Study Group of the AIEOP (Italian Association of Paediatric Haematology Oncology) Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol 2008;140:197-205.
14. Scheinberg Ph, Wu CO, Nunez O, Scheinberg Pr, Boss C, Sloand EM, Young NS. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 2009; 94:348-54.
15. Tichelli A, Passweg J, Nissen C, Bargetzi M, Hoffmann T, Filipowicz A, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol 1998;100:393-400.
16. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and cyclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006;133:622-7.
17. Di Bona E, Rodeghiero F Bruno B, Gabbas A, Foa P, Localsciulli A, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br J Haematol 1999; 107:330-4.
18. Gupta V Gordon-Smith E, Cook G, Parker A, Duguid J, Wilson K, et al. A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders. Br J Haematol 2005;128:110-7.
19. Scheinberg P, Nunez O, Wu C, Young N. Treatment of severe aplastic anaemia with combined immunosuppression: antithymocyte globulin, cyclosporin and mycophenolate mofetil. Br J Haematol 2006;133:606-11.
20. Tisdale J, Dunn D, Geller N, Plante M, Nunez O, Dunbar C, et al. High dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet 2000;356:1554-9.
21. Gluckman E, Rokicka-Milewska R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S, et al. and the European Group for Blood and Marrow Transplantation Working Party for Severe Aplastic Anaemia. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patientswith severe aplastic anaemia. Br J Haematol 2002;119:1075-82.
22. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol 2006;34:826-31.
23. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509-19.